Regeneron Pharmaceuticals, Inc.
Matrix Extracellular Phosphoglycoprotein (MEPE) Variants And Uses Thereof

Abstract:

Methods of treating patients having decreased bone mineral density and/or osteoporosis, methods of identifying subjects having an increased risk of developing decreased bone mineral density and/or osteoporosis, and methods of diagnosing decreased bone mineral density and/or osteoporosis in a human subject, comprising detecting the presence of Matrix Extracellular Phosphoglycoprotein (MEPE) predicted loss-of-function variant nucleic acid molecules and polypeptides in a biological sample from the patient or subject, are provided herein.